Last reviewed · How we verify
sodium hyaluronate 0.18%
Sodium hyaluronate is a viscoelastic substance that lubricates and protects the ocular surface by mimicking natural tear film.
Sodium hyaluronate is a viscoelastic substance that lubricates and protects the ocular surface by mimicking natural tear film. Used for Dry eye disease, Ocular surface protection during ophthalmic surgery.
At a glance
| Generic name | sodium hyaluronate 0.18% |
|---|---|
| Also known as | VISMED® Multi, Vismed® |
| Sponsor | Allergan |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Sodium hyaluronate is a naturally occurring polysaccharide that acts as a humectant and lubricant on the eye surface. It binds water and forms a protective layer over the cornea and conjunctiva, reducing friction and providing sustained hydration. This mechanism makes it effective for treating dry eye disease and protecting the ocular surface during and after ophthalmic procedures.
Approved indications
- Dry eye disease
- Ocular surface protection during ophthalmic surgery
Common side effects
- Blurred vision
- Eye irritation
- Mild ocular discomfort
Key clinical trials
- Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. (PHASE4)
- Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease (NA)
- Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel (PHASE1)
- A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye (NA)
- The Effect of Gland Expression on the Regeneration of Meibomian Gland (NA)
- Efficacy of 0.28% Sodium Hyaluronate Eye Drops in Patient with Moderate to Severe Dry Eye (PHASE4)
- Efficacy of 0.38% and 0.18% Sodium Hyaluronate Ocular Lubricants for Dry Eye in Adult Gazan Participants (PHASE2)
- Safety and Efficacy of 2 Concentrations of Lubricin vs Sodium Hyaluronate in Ocular Discomfort After Refractive Surgery. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sodium hyaluronate 0.18% CI brief — competitive landscape report
- sodium hyaluronate 0.18% updates RSS · CI watch RSS
- Allergan portfolio CI